{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:29:49Z","timestamp":1789349389357,"version":"build-2803163510"},"reference-count":157,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2015,10,2]],"date-time":"2015-10-02T00:00:00Z","timestamp":1443744000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["journals.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>SUMMARY<\/jats:title>\n                  <jats:p>Human papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most common cancer and cause of cancer-related death in females worldwide. HPV also causes anal, vaginal, vulvar, penile, and oropharyngeal cancer. Prophylactic HPV vaccines based on recombinantly expressed virus-like particles have been developed. Two first-generation, U.S. Food and Drug Administration (FDA)-approved vaccines prevent infections and disease caused by HPV16 and HPV18, the two HPV genotypes that cause approximately 70% of cervical cancer, and one of these vaccines also prevents HPV6 and HPV11, the two HPV genotypes that cause 90% of genital warts. A next-generation vaccine, recently approved by the U.S. FDA, targets HPV16, HPV18, and five additional HPV genotypes that together causes approximately 90% of cervical cancer as well as HPV6 and HPV11. In clinical trials, these vaccines have shown high levels of efficacy against disease and infections caused by the targeted HPV genotypes in adolescent females and males and older females. Data indicate population effectiveness, and therefore cost effectiveness, is highest in HPV-naive young females prior to becoming sexually active. Countries that implemented HPV vaccination before 2010 have already experienced decreases in population prevalence of targeted HPV genotypes and related anogenital diseases in women and via herd protection in heterosexual men. Importantly, after more than 100 million doses given worldwide, HPV vaccination has demonstrated an excellent safety profile. With demonstrated efficacy, cost-effectiveness, and safety, universal HPV vaccination of all young, adolescent women, and with available resources at least high-risk groups of men, should be a global health priority. Failure to do so will result in millions of women dying from avertable cervical cancers, especially in low- and middle-income countries, and many thousands of women and men dying from other HPV-related cancers.<\/jats:p>","DOI":"10.1017\/s0950268815002198","type":"journal-article","created":{"date-parts":[[2015,10,2]],"date-time":"2015-10-02T03:12:23Z","timestamp":1443755543000},"page":"449-468","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":163,"title":["Prophylactic HPV vaccination: past, present, and future"],"prefix":"10.1017","volume":"144","author":[{"given":"P. E.","family":"CASTLE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"MAZA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2015,10,2]]},"reference":[{"key":"S0950268815002198_ref147","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004952"},{"key":"S0950268815002198_ref146","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0775"},{"key":"S0950268815002198_ref148","unstructured":"Anon. (http:\/\/gamapserver.who.int\/gho\/interactive_charts\/health_financing\/atlas.html). 2014. Accessed 21 December 2014."},{"key":"S0950268815002198_ref142","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs425"},{"key":"S0950268815002198_ref135","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji187"},{"key":"S0950268815002198_ref125","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b3884"},{"key":"S0950268815002198_ref120","doi-asserted-by":"publisher","DOI":"10.1002\/bit.25311"},{"key":"S0950268815002198_ref99","unstructured":"Anon. 2015 (http:\/\/www.nhs.uk\/conditions\/vaccinations\/pages\/vaccination-schedule-age-checklist.aspx). Accessed 22 June 2015."},{"key":"S0950268815002198_ref96","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"S0950268815002198_ref86","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12226"},{"key":"S0950268815002198_ref77","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2032"},{"key":"S0950268815002198_ref141","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs135"},{"key":"S0950268815002198_ref131","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/cncr.25065","article-title":"Cervical cancer prevention: new tools and old barriers","volume":"116","author":"Scarinci","year":"2010","journal-title":"Cancer"},{"key":"S0950268815002198_ref116","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.202"},{"key":"S0950268815002198_ref94","unstructured":"WHO. Evidence based recommendations on human papilloma virus (HPV) vaccine schedules, 2014. World Health Organization. 5\u201327\u20132014. (http:\/\/www.who.int\/immunization\/sage\/meetings\/2014\/april\/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf). Accessed 23 August 2015."},{"key":"S0950268815002198_ref61","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu139"},{"key":"S0950268815002198_ref60","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu104"},{"key":"S0950268815002198_ref53","doi-asserted-by":"publisher","DOI":"10.4161\/hv.27925"},{"key":"S0950268815002198_ref101","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.01.004"},{"key":"S0950268815002198_ref82","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28607"},{"key":"S0950268815002198_ref40","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-227"},{"key":"S0950268815002198_ref68","doi-asserted-by":"publisher","DOI":"10.1086\/428779"},{"key":"S0950268815002198_ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1625"},{"key":"S0950268815002198_ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2569"},{"key":"S0950268815002198_ref11","doi-asserted-by":"publisher","DOI":"10.1186\/1750-9378-4-8"},{"key":"S0950268815002198_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61416-0"},{"key":"S0950268815002198_ref154","unstructured":"Anon. GDP per capita (current US$). 2014 (http:\/\/databank.worldbank.org\/data\/views\/reports\/tableview.aspx). Accessed 23 December 2014."},{"key":"S0950268815002198_ref81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068329"},{"key":"S0950268815002198_ref151","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.098"},{"key":"S0950268815002198_ref50","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.12.18281"},{"key":"S0950268815002198_ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-07-2691"},{"key":"S0950268815002198_ref69","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22241"},{"key":"S0950268815002198_ref111","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01577-07"},{"key":"S0950268815002198_ref108","doi-asserted-by":"publisher","DOI":"10.1006\/viro.2000.0272"},{"key":"S0950268815002198_ref13","unstructured":"Freeman HP , Wingrove BK . Excess cervical cancer mortality: a marker for low access to health care in poor communities. National Institutes of Health; 2007. Report No. 05\u20135282."},{"key":"S0950268815002198_ref149","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70237-2"},{"key":"S0950268815002198_ref43","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-13-0203"},{"key":"S0950268815002198_ref92","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ364"},{"key":"S0950268815002198_ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.04.068"},{"key":"S0950268815002198_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70103-7"},{"key":"S0950268815002198_ref107","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000694"},{"key":"S0950268815002198_ref65","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.95"},{"key":"S0950268815002198_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.01.084"},{"key":"S0950268815002198_ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.011"},{"key":"S0950268815002198_ref36","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit360"},{"key":"S0950268815002198_ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061760"},{"key":"S0950268815002198_ref75","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29266"},{"key":"S0950268815002198_ref47","doi-asserted-by":"publisher","DOI":"10.1086\/521679"},{"key":"S0950268815002198_ref87","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12329"},{"key":"S0950268815002198_ref72","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2011-050234"},{"key":"S0950268815002198_ref115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039741"},{"key":"S0950268815002198_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70230-8"},{"key":"S0950268815002198_ref20","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e31825c31dd"},{"key":"S0950268815002198_ref70","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis590"},{"key":"S0950268815002198_ref155","unstructured":"Ferlay J , GLOBOCAN 2012 v. 1\u00b70, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. 2013. Lyon, France, International Agency for Research on Cancer."},{"key":"S0950268815002198_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70841-2"},{"key":"S0950268815002198_ref95","unstructured":"Anon. 2015 (http:\/\/vacunasaep.org\/sites\/vacunasaep.org\/files\/CalVacAEP_2015_PRINCIPAL_tabla.pdf). Accessed 5 January 2015."},{"key":"S0950268815002198_ref23","first-page":"1","article-title":"Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"Morbidity and Mortality Weekly Report Recommendations and Reports"},{"key":"S0950268815002198_ref139","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt235"},{"key":"S0950268815002198_ref156","unstructured":"WHO. 2015 (http:\/\/gamapserver.who.int\/gho\/interactive_charts\/health_financing\/atlas.htm). WHO. Accessed 2015."},{"key":"S0950268815002198_ref143","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25915"},{"key":"S0950268815002198_ref89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009886.pub2"},{"key":"S0950268815002198_ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.08.106"},{"key":"S0950268815002198_ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2007.02.015"},{"key":"S0950268815002198_ref134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.12.003"},{"key":"S0950268815002198_ref51","doi-asserted-by":"publisher","DOI":"10.4161\/hv.5.10.9518"},{"key":"S0950268815002198_ref73","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(10)70225-5"},{"key":"S0950268815002198_ref97","unstructured":"Anon. 2015 (http:\/\/www.phac-aspc.gc.ca\/publicat\/ccdr-rmtc\/12vol38\/acs-dcc-1\/index-eng.php). Accessed 22 June 2015."},{"key":"S0950268815002198_ref153","unstructured":"Anon. 2015 (http:\/\/www.paho.org\/hq\/index.php?option=com_content&view=article&id=1864&Itemid=40713&lang=en). Accessed 6 January 2015."},{"key":"S0950268815002198_ref127","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir285"},{"key":"S0950268815002198_ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2008.10.002"},{"key":"S0950268815002198_ref59","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir209"},{"key":"S0950268815002198_ref78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909537"},{"key":"S0950268815002198_ref117","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-003-0119-4"},{"key":"S0950268815002198_ref74","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit192"},{"key":"S0950268815002198_ref64","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr319"},{"key":"S0950268815002198_ref132","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq382"},{"key":"S0950268815002198_ref30","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0131"},{"key":"S0950268815002198_ref28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp534"},{"key":"S0950268815002198_ref80","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70213-3"},{"key":"S0950268815002198_ref137","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2968"},{"key":"S0950268815002198_ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.014"},{"key":"S0950268815002198_ref24","first-page":"7","article-title":"American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors","volume":"57","author":"Saslow","year":"2007","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"S0950268815002198_ref58","article-title":"Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345 years: end-of-study analysis of a Phase III randomized trial","author":"Takacs","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"S0950268815002198_ref63","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.407"},{"key":"S0950268815002198_ref18","first-page":"5","volume":"16","year":"1988","journal-title":"New Zealand Nursing Forum"},{"key":"S0950268815002198_ref105","unstructured":"Anon. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. 2015 (http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm426485.htm). Accessed 3 April 2015."},{"key":"S0950268815002198_ref123","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.404"},{"key":"S0950268815002198_ref26","first-page":"630","article-title":"FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","year":"2010","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"S0950268815002198_ref45","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0461"},{"key":"S0950268815002198_ref100","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f5906"},{"key":"S0950268815002198_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.07.055"},{"key":"S0950268815002198_ref122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa0707052"},{"key":"S0950268815002198_ref44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603469"},{"key":"S0950268815002198_ref104","unstructured":"Anon. Global Advisory Committee on Vaccine Safety. Statement on the continued safety of HPV vaccination. 2014 (http:\/\/www.who.int\/vaccine_safety\/committee\/topics\/hpv\/GACVS_Statement_HPV_12_Mar_2014.pdf). Accessed 9 November 2014."},{"key":"S0950268815002198_ref106","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"S0950268815002198_ref113","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.15.8386-8393.2003"},{"key":"S0950268815002198_ref1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.80.12.3812"},{"key":"S0950268815002198_ref56","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-4144"},{"key":"S0950268815002198_ref19","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt077"},{"key":"S0950268815002198_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70187-1"},{"key":"S0950268815002198_ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.12.039"},{"key":"S0950268815002198_ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.067"},{"key":"S0950268815002198_ref129","article-title":"Expanding the national HPV immunisation program to include males: a health-economic approach and decision-making","author":"Conway","year":"2013","journal-title":"HPV Today"},{"key":"S0950268815002198_ref98","unstructured":"Anon. 2015 (http:\/\/www.immunise.health.gov.au\/internet\/immunise\/publishing.nsf\/Content\/national-immunisation-program-schedule). Accessed 22 June 2015."},{"key":"S0950268815002198_ref103","first-page":"591","article-title":"Human papillomavirus vaccination coverage among adolescent girls, 2007\u20132012, and postlicensure vaccine safety monitoring, 2006\u20132","volume":"62","year":"2013","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"S0950268815002198_ref4","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2635"},{"key":"S0950268815002198_ref157","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60270-X"},{"key":"S0950268815002198_ref10","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31828b6be4"},{"key":"S0950268815002198_ref62","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24340"},{"key":"S0950268815002198_ref90","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00047-9"},{"key":"S0950268815002198_ref145","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit577"},{"key":"S0950268815002198_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70286-8"},{"key":"S0950268815002198_ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-09-0031"},{"key":"S0950268815002198_ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.07.027"},{"key":"S0950268815002198_ref124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089974"},{"key":"S0950268815002198_ref71","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1458"},{"key":"S0950268815002198_ref79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010971"},{"key":"S0950268815002198_ref85","doi-asserted-by":"publisher","DOI":"10.1086\/656320"},{"key":"S0950268815002198_ref88","unstructured":"Anon. Evaluation of safety and immunogenicity of a human papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) infected females, 2014 (http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01031069?term=HIV+HPV+vaccination&rank=11). Accessed 23 August 2015."},{"key":"S0950268815002198_ref112","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp106"},{"key":"S0950268815002198_ref152","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.11.097253"},{"key":"S0950268815002198_ref33","unstructured":"WHO. Human papillomavirus vaccines: WHO position paper, October 2014. Geneva, Switzerland: WHO, 2014. Report No.: 43."},{"key":"S0950268815002198_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji073"},{"key":"S0950268815002198_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq356"},{"key":"S0950268815002198_ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.7.743"},{"key":"S0950268815002198_ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.096"},{"key":"S0950268815002198_ref83","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61050-2"},{"key":"S0950268815002198_ref57","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29532"},{"key":"S0950268815002198_ref136","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1055-9965.EPI-13-0053","article-title":"Age-specific occurrence of HPV16- and HPV18-related cervical cancer","volume":"22","author":"de","year":"2013","journal-title":"Cancer Epidemiology, Biomarkers and Prevention"},{"key":"S0950268815002198_ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.12.037"},{"key":"S0950268815002198_ref140","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28616"},{"key":"S0950268815002198_ref121","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu413"},{"key":"S0950268815002198_ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27608"},{"key":"S0950268815002198_ref138","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e318285423c"},{"key":"S0950268815002198_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(12)70187-1"},{"key":"S0950268815002198_ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26250"},{"key":"S0950268815002198_ref54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061825"},{"key":"S0950268815002198_ref114","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01088-09"},{"key":"S0950268815002198_ref144","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1812"},{"key":"S0950268815002198_ref133","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPTUS5EXAS6DKZ"},{"key":"S0950268815002198_ref110","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00936-07"},{"key":"S0950268815002198_ref2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/003591576505800503","article-title":"The environment and disease: association or causation?","volume":"58","author":"Hill","year":"1965","journal-title":"Proceedings of the Royal Society of Medicine"},{"key":"S0950268815002198_ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27485"},{"key":"S0950268815002198_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70287-X"},{"key":"S0950268815002198_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70110-4"},{"key":"S0950268815002198_ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-014-0406-2"},{"key":"S0950268815002198_ref39","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt460"},{"key":"S0950268815002198_ref76","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71073-4"},{"key":"S0950268815002198_ref91","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5009"},{"key":"S0950268815002198_ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.06.054"},{"key":"S0950268815002198_ref130","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs491"},{"key":"S0950268815002198_ref126","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-351"},{"key":"S0950268815002198_ref109","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2560"},{"key":"S0950268815002198_ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2010.02.002"},{"key":"S0950268815002198_ref150","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.120"},{"key":"S0950268815002198_ref25","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","year":"2010","journal-title":"Morbidity and Mortality Weekly Report"}],"updated-by":[{"DOI":"10.1017\/s0950268816000777","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T00:00:00Z","timestamp":1461888000000}}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268815002198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T10:32:51Z","timestamp":1718101971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268815002198\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,2]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0950268815002198"],"URL":"https:\/\/doi.org\/10.1017\/s0950268815002198","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,2]]},"assertion":[{"value":"Copyright \u00a9 Cambridge University Press 2015\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}